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Abstract
Background: Xenotropic murine leukemia-related retrovirus (XMRV) is a recently discovered retrovirus that has been linked
to human prostate cancer and chronic fatigue syndrome (CFS). Both diseases affect a large fraction of the world population,
with prostate cancer affecting one in six men, and CFS affecting an estimated 0.4 to 1% of the population.
Principal Findings: Forty-five compounds, including twenty-eight drugs approved for use in humans, were evaluated
against XMRV replication in vitro. We found that the retroviral integrase inhibitor, raltegravir, was potent and selective
against XMRV at submicromolar concentrations, in MCF-7 and LNCaP cells, a breast cancer and prostate cancer cell line,
respectively. Another integrase inhibitor, L-000870812, and two nucleoside reverse transcriptase inhibitors, zidovudine
(ZDV), and tenofovir disoproxil fumarate (TDF) also inhibited XMRV replication. When combined, these drugs displayed
mostly synergistic effects against this virus, suggesting that combination therapy may delay or prevent the selection of
resistant viruses.
Conclusions: If XMRV proves to be a causal factor in prostate cancer or CFS, these discoveries may allow for rational design
of clinical trials.
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Introduction
Xenotropic murine leukemia-related retrovirus (XMRV) is a
recently discovered infectious agent [1] that has been linked to
human prostate cancer [2] and chronic fatigue syndrome (CFS)
[3]. Both diseases affect a large fraction of the world population,
with prostate cancer affecting one in six men, and CFS affecting
an estimated 0.4 to 1% of the population [4], [5]. XMRV nucleic
acid or proteins are found in 27% of prostate cancers and in 68%
of chronic fatigue syndrome patients, and in less than 4–6% of
normal controls, suggesting an association between the virus and
human disease [2,3].
CFS, a disease characterized by severe debilitating fatigue, has
had an uncertain etiology since its recognition. While a series of
viral agents and environmental toxins have been proposed to be
associated with CFS, no clear evidence for these has ever been
presented (reviewed in [6]). The recent association of XMRV with
CFS from the Whittemore Peterson Institute in Reno, Nevada,
while far from being proven causal, is the strongest viral
association to be made yet. Three recent reports, using plasmid
DNA as positive controls, did not find XMRV in CFS patients in
Europe [7] [8] [9]. The prevalence of XMRV in prostate cancer
in Europe is uncertain, with one German group reporting the
presence of XMRV in human prostates [10], and the other not
detecting any [11]. However, the notion that a retrovirus might be
involved in both cancer and a neuroimmune illness in humans is
not without precedence. Human T-cell lymphotrophic virus, type
1 (HTLV-1), another retrovirus, causes both T-cell lymphoma/
leukemia as well as tropical spastic paraparesis, a myelopathy due
to immune defects resulting from the viral infection.
Infectious XMRV has been isolated from sera of CFS patients
[3]. The presence of circulating infectious retrovirus particles in
the blood invokes a scenario not unlike infection with another
retrovirus, human immunodeficiency virus type 1 (HIV-1). Since
there is no effective treatment for this profoundly debilitating
illness, the use of antiretroviral agents that have proven to be
reasonably safe for human use, might be of benefit. The discovery
of effective antiretroviral agents against XMRV would allow for
rational design of clinical trials to prevent progression of prostate
cancer or to treat CFS.
In this study, we report the effect of 45 compounds on XMRV
replication in MCF-7 and LNCaP cells, cell lines generated from
human breast and prostate cancers, respectively. We studied drugs
used in the treatment of HIV-1 infections, as well as compounds
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gammaretrovirus, closely related to the murine leukemia viruses
(MLV) [1]. At the amino acid level, it shares considerable identity
with sequences of Moloney murine leukemia virus (MoMLV), a
prototype MLV. The maximum similarity between XMRV and
MoMLV proteins is found in the sequences for viral protease (96%
identity), and the least similarity is between the two envelope
proteins (66% identity) [1]. Unfortunately, not many actively-used
antiretroviral agents have been tested for activity against MLV,
with the exception of ZDV, which effectively suppresses MLV
[12], and was recently demonstrated to be effective against
XMRV as well [13]. In contrast, while there is a lot of information
on antiviral activity against essential HIV-1 proteins, there is very
little similarity between HIV-1 and XMRV proteins, with the
proteases (PR) of the two viruses sharing 28% identity at the amino
acid level, the reverse transcriptase proteins (RT) sharing 17% and
the integrase (IN) proteins sharing just 14% identity. This low
sequence similarity makes it difficult to predict which, if any, of the
antiretroviral agents that are effective against HIV-1 would be
effective against XMRV. We chose several drugs from each major
class of antiretroviral agents: nucleoside and non-nucleoside
RT inhibitors (NRTIs and NNRTIs), IN inhibitors, and PR
inhibitors (PI). The envelope proteins of the XMRV and HIV-1
are widely divergent in size (70k Da n d1 6 0k Dr e s p e c t i v e l y ) ,
utilize different receptors for viral entry and do not share any
significant similarity. Therefore, peptidomimetics that act on the
HIV-1 envelope protein to prevent viral entry were not included
in our study. A few inhibitors that are known to inhibit
replication of viruses other than retroviruses were also
evaluated. A significant number of compounds tested in our
study, viz. 28 out of a total of 45, are already FDA-approved for
the treatment of infection with HIV-1 or other viruses. We
report here for the first time that the integrase inhibitor,
raltegravir (RAL), is extremely potent and selective against
XMRV, when used at low submicromolar concentrations in
both cell culture systems. Another IN inhibitor, L-000870812,
and two NRTIs, ZDV and tenofovir disoproxil fumarate (TDF),
also inhibit XMRV replication, but at higher concentrations.
When combined, these compounds display synergistic effects,
suggesting combined modalities to treat XMRV infection, thus
delaying or preventing the selection of resistant viruses.
Results
We tested a total of 45 compounds belonging to different classes
of HIV-1 inhibitors, and a few inhibitors of viruses other than
retroviruses, for their ability to inhibit XMRV replication in
cultured cells. LNCaP and MCF-7 cells were chosen for their
ability to support robust in vitro replication of XMRV. MCF-7
cells, because of their better growth properties in culture were
initially used to test all 45 compounds (Figure 1). Compounds with
anti-XMRV activity were subsequently tested in both LNCaP and
MCF-7 cells (Table S1). To determine if a reduction in viral
release might be due to toxicity of the compound and not due to
specific antiretroviral activity, cellular morphology was monitored
every 24 h by microscopic examination, and an MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] colorimet-
ric assay was used to measure potential cytotoxicity produced by
the compounds. Supernatants were collected every 24 h and
assayed for viral release by measuring RT activity. Inhibition of
RT activity (see Figure 2) was averaged over 3–6 experiments,
each performed in duplicate, and used to calculate the median
(EC50) and 90% effective concentrations (EC90) for each
compound (Figure 1). For comparison purposes, all compounds
evaluated in these studies were also tested against HIV-1LAI in
primary human lymphocytes.
Inhibitors of HIV-1 reverse transcriptase
The following NRTI inhibitors of HIV-1 RT were tested in our
XMRV replication assays: ZDV, 39-azido-39-deoxyadenosine
(AZA), 39-azido-39-deoxyguanosine (AZG), 39-azido-39-deoxy-5-
methyl-cytidine (CS-92), lamivudine (3TC), emtricitabine [(-)-
FTC], tenofovir (TNV) and its prodrug form TDF, 9-(b-D-1,
3-dioxolan-4-yl)guanine (DXG) and its prodrug form, amdoxovir
(DAPD, AMDX), (-)-carbovir (CBV), stavudine (D4T) and its
corresponding cytosine analog (D4C), videx (ddI), zalcitabine
(ddC), and 39-fluoro-39-deoxythymidine (FLT). We also tested
the NNRTIs efavirenz, and a TIBO derivative that was shown
to be effective in a murine system [14]. Among these, the most
potent XMRV inhibitors were ZDV and TDF (Figure 2, A, B).
The EC50 and EC90 in MCF-7 cells were 0.11 mMa n d7 . 3mM
for ZDV, and 0.24 mMa n d1 5 . 3mM for TDF respectively (see
Figure 1). The EC50 and EC90 values were also determined in
LNCaP cells, a prostate cancer cell line, and there was a
consistent difference of up to 5 fold between the two cell lines,
which may be related to their differing rates of nucleoside
uptake and bioconversion to the active nucleoside triphosphate
analog. The EC50 and EC90 in LNCaP cells were 0.14 mMa n d
1.1 mMf o rZ D V ,a n d0 . 9 mMa n d4 . 2 mMf o rT D F ,
respectively. CBV, AZA, FLT and D4T all showed greater
than 70% inhibition of XMRV replication (see Table S1), but at
the much higher concentration of 100 mM. AZG, CS-92, (-)-
FTC, 3TC, ddI, DAPD and DXG were essentially inactive at
100 mM (Figure 1). TFV was also ineffective against XMRV,
probably due to its polar nature, which may not allow sufficient
drug to penetrate into the cells. The NNRTIs efavirenz (EFV)
and the TIBO derivative, did not demonstrate any major
activity against XMRV.
Inhibitors of HIV-1 Integrase
IN inhibitors raltegravir (RAL or MK-0518) and L-000870812
[15] were also evaluated for their ability to inhibit XMRV in the
two cell systems (Figure 1, Figure 2 C and D). Of all the
compounds tested, RAL was the most potent, with an EC50 of
0.005 mM and an EC90 of 3.5 mM in MCF-7 cells, and an EC50 of
0.03 mM and an EC90 of 0.46 mM in LNCaP cells (Table S1). L-
000870812, showed activity against XMRV replication at
considerably higher concentrations, with an EC50 and EC90 of
0.16 mM and 26.9 mM in MCF-7 cells, and 0.7 mM and 4.5 mMi n
LNCaP cells, respectively.
Inhibitors of HIV-1 Protease
Nine known HIV-1 PIs were evaluated for activity against
XMRV (Figure 1). The most effective was nelfinavir, albeit with
an EC50 of 34.3 mM. The following PIs had very modest anti-
XMRV activities: atazanavir (EC50 of 64.8 mM), amprenavir
(EC50 of 68.0 mM), lopinavir (EC50 of 72.2 mM), and ritonavir
(EC50 of 76.4 mM). Darunavir, indinavir, saquinavir and tiprana-
vir were essentially ineffective against XMRV in vitro, when tested
up to 100 mM.
Inhibitors of viruses other than HIV-1
A select number of antiviral agents known to inhibit viruses
other than retroviruses were also evaluated. These included the
anti-herpetic drugs acyclovir (ACV), ganciclovir (GCV), vidar-
abine (ara-A), 5-Iodo-29-deoxyuridine (IdUrd), penciclovir
(PCV), foscarnet (PFA), vistide (HPMPC); the anti-hepatitis
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ETV was also selected because it was recently reported to
inhibit HIV-1 replication, both in vitro and in humans [16].
Other compounds claimed to be effective against XMRV,
MLV, HIV-1 and other viruses, such as chloroquine [17],
dehydroepiandrosterone (DHEA) [18], methylene blue and
aspirin were also evaluated for anti-XMRV activity in vitro.
Methylene blue is known to have antiherpetic activity and also
can inactivate HIV-1 [19]. Unfortunately, most of the
compounds listed above, except IdUrd were ineffective against
XMRV, or were effective at toxic concentrations (Figure 1).
IdUrd demonstrated a low therapeutic index (TI, the ratio of
CC50/EC50) and cannot be considered as a specific antiviral
agent against XMRV.
Figure 1. EC50,E C 90 and CC50 values of compounds tested in XMRV-infected MCF-7 cells, and in HIV-1 infected peripheral blood
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replication
Binary combinations of the most potent compounds, viz. RAL,
L-000870812, TDF and ZDV were tested for activity against
XMRV in LNCaP cells. Compounds were tested at increasing
concentrations, in three different sets, with the ratio of the two
compounds kept constant. The data were analyzed using the
CalcuSyn method originally described by Chou and Talalay [20].
A summary of results for all combinations evaluated in LNCaP
cells is presented in Figure 3.
For the combinations tested (RAL with TDF or ZDV or L-
000870812; TDF with ZDV or L-000870812; L-000870812 with
ZDV), an additive or mostly synergistic interaction was noted at all
effect levels without apparent cytotoxicity at the highest concen-
trations used. In the computational analysis for either one of the
four drugs (RAL, TDF, L-000870812, or ZDV), the linear
correlation coefficient (r values) of the median-effect plot or for
their constant ratio combinations ranged from 0.92 to 0.99 (data
not shown), matching the law of mass-action. The in vitro effect of
the combination of RAL with either TDF or ZDV, showed a
favorable dose reduction at all ratios. In addition, all Combination
Index (CI) values (see Materials and Methods) were less than 1,
suggesting synergy when the combination ratios of either TDF or
ZDV and RAL were analyzed (Figure 3). In addition, dual
combinations of either ZDV and L-000870812 or TDF were also
tested. The weighted CI (CIwt) values of 0.1 to 0.5 for TDF +
ZDV, indicated synergistic effects at all ratios tested (Figure 3).
Moreover, the dual combination of L-000870812 and ZDV at
ratio 1:2 indicated a nearly additive effect (CIwt of 1.0); however at
ratio of 1:0.4, the CI value was 0.3, indicating synergism (Figure 3).
Of significance was that all dual combinations containing RAL,
the most potent antiviral agent against XMRV, demonstrated
marked synergy at all effect levels without any apparent
cytotoxicity. Interestingly, the combination of the two IN
inhibitors was not antagonistic or additive, but was found to be
synergistic, suggesting that these two compounds may have
different antiviral mechanisms (see discussion).
Discussion
In the absence of a clear etiology, the treatment of CFS has
been both empirical and unconventional. Therapies have included
immunostimulant therapy through injections of staphylococcus
toxoid [21], intravenous immunoglobulin therapy [22] [23][24],
and hydrocortisone [25] each with uneven results. Interferon-b
and TNF-a inhibitors have been tried in very small numbers of
patients. Anti-depressants, NSAIDs, anxiolytic drugs, stimulants,
anti-allergy drugs and anti-hypotensive drugs have all been used,
but are not universally beneficial [26]. The lack of effective
therapy has led to use of plant extracts [27], homeopathy [28,29],
hypnosis [30], acupuncture [31], and whole body periodic
acceleration stress [32], none with sustained benefits. The only
modalities of treatment that have any proven benefits are cognitive
Figure 2. Inhibition of XMRV replication in LNCaP cells in the presence of increasing concentrations of antiviral agents. Viral release from
XMRV-infected LNCaP cells in the presence of increasing concentrations of (A) ZDV (B) TDF (C) RAL and (D) L-000870812, was determined by measuring
RT activity in the supernatants. Percent inhibition was calculated based on infected cells exposed to DMSO alone being set to 0% inhibition, and naı ¨ve
cells in the absence of any compounds set at 100% inhibition. Cell viability was checked by microscopy, quantified by the MTT assay, and represented by
shaded bars. Data for each compound were derived from an average of at least three independent experiments, each performed in duplicate.
doi:10.1371/journal.pone.0009948.g002
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appear to aid by improving coping skills rather than reduce
symptoms [33]. If, XMRV proves to have a causal association
with human disease, then the knowledge that certain antiretroviral
agents inhibit XMRV at submicromolar concentrations in vitro,
and have synergistic effects when combined, as shown in this
study, might lead to clinical trials. We found that RAL, L-
000870812, ZDV, and TDF strongly inhibit XMRV in cell
culture, with RAL being the most potent, at an EC50 of 0.005 mM,
and others such as L-000870812 (EC50=0.16 mM), ZDV
(EC50=0.11 mM) and TDF (EC50=0.24 mM) being quite effec-
tive as well. In addition, these compounds had high therapeutic
indices, with values for ZDV=591; TDF=218; RAL=18,460
and L-000870812=378, indicating that it should be possible to
achieve therapeutic antiviral levels with minimal toxicity.
Several compounds that we evaluated had a limited effect on
XMRV replication in vitro. Some of these effects can be explained
by currently understood mechanisms. For example, both 3TC and
(-)-FTC need a functional YMDD motif in RT to be active. The
M184V mutation in HIV-1 RT makes the virus resistant to 3TC
and (-)-FTC [34]. These drugs are ineffective against MoMLV,
because in MoMLV RT, V is the natural residue in this motif in
place of M. Similarly, V is also the natural residue at this location
in XMRV RT, making 3TC and (-)-FTC ineffective. Why none of
the HIV-1 PIs were effective against XMRV (a finding that has
been reported for selected PIs before [13]) remains unclear at this
time, but could be related to the size of the PI pocket as well as
other biochemical and structural factors.
There was a difference in activities of compounds when tested in
different cell types, which may be related to drug uptake by cells,
the different levels of natural dNTP in the cells, as well as different
intracellular phosphorylation capacity [35]. In general, the EC50
for the active compounds listed above were lower in MCF-7 than
LNCaP cells suggesting greater potency. Relative to HIV-1, the
compounds were generally less potent against XMRV than HIV-
1, especially at the EC90 level.
The use of monotherapy for treating HIV infections has lead to
the appearance of drug resistant virus [36,37]. The finding that
RAL, L-000870812, TDF and ZDV have strong synergistic effects
when combined in dual combination bodes well for combination
therapy in case of XMRV infection. If XMRV infection parallels
other retroviral infections, then the use of combination antiretro-
viral therapy might maintain XMRV suppression, prevent the
emergence of resistance to antiretroviral agents and possibly also
cause amelioration of disease. For HIV-1, combination therapy
works especially well when the combined drugs have different viral
protein targets, or in the case of nucleosides, utilize different
kinases for their activation to NTP analogs [31]. We, therefore,
judiciously selected drug combinations that inhibit XMRV, such
as RAL with ZDV or TDF or L-000870812. When the data were
analyzed using the robust method of Chou and Talalay, additive
or synergistic interactions were found at all effect levels when these
agents were tested in LNCaP cells. Of significance was that no
antagonism was noted for any of the combinations evaluated in
these cells. To our surprise, even the two IN inhibitors displayed a
synergistic effect. Both IN inhibitors act by inhibiting the strand
transfer reaction, but if their mechanism of action were to be
identical, they would display an additive effect in combination. A
synergistic effect suggests that there might be subtle mechanistic
differences in the actions of these two IN inhibitors, a finding that
is corroborated by unpublished biochemical experiments (personal
communication, Dr. Daria Hazuda, Merck Research Laborato-
ries, West Point, PA). It is important to note here, that XMRV
differs from HIV-1 in one aspect that is significant for these
studies: XMRV isolates show very limited sequence diversity
compared to HIV-1 or MLV. Of all the sequenced XMRV
isolates that currently exist, both from cases with prostate cancer as
well as CFS, obtained from geographically distant parts of the
United States, the two least related genomes differ from each other
in only 27 out of a total of over 8,100 nucleotides. A similar degree
of limited genetic diversity has been found for HTLV-1 [38],
another retrovirus implicated in both cancer and neuroimmune
illness. It has been suggested that this lack of diversity in XMRV
sequences implies that the number of replication cycles within one
infected individual is limited [39]. This would suggest that XMRV
has a considerably lower potential for developing drug-resistant
Figure 3. Evaluation of drug-drug interactions against XMRV at 50%, 75%, 90%, and 95% inhibition. Combination Index (CI) values
were determined for a mutually exclusive interaction using CalcuSyn program, where CI ,1 indicates synergism, CI=1 indicates additive effect, and
CI .1 indicates antagonism. Weighted average CI value (CIwt) was assigned as [CI50 + 2CI75 + 3CI90 + 4CI95]/10. RAL, raltegravir; TDF, tenofovir
disoproxil fumarate; ZDV, zidovudine.
doi:10.1371/journal.pone.0009948.g003
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combination of just two drugs might be sufficient for preventing
the emergence of drug-resistant mutant virus, though this would
need to be tested before any therapeutic recommendations can be
made. We have attempted to select for RAL resistant viruses in
culture for several months now, and have not yet been successful at
isolating drug resistant viruses.
When an assay to measure XMRV viral loads becomes
available, virus levels in the blood might become an objective
surrogate marker for an effective response to antiviral drugs, in
addition to clinical outcomes. While it is not yet clear if any
illnesses are directly caused by XMRV, our data indicates that
XMRV infections might be prevented or treated with specific
antiviral agents. In the presence of any evidence of causality of
human disease, our findings should provide the basis for designing
clinical trials to treat them.
Materials and Methods
XMRV, Cells and Infection with XMRV
293T cells (ATCC, CRL-11268) were transfected with
pXMRV1, an infectious clone of XMRV [2]. Virus released in
the supernatant was harvested and titrated by inoculating MCF-7
cells, a breast cancer cell line (ATCC, HTB-22) at 70%
confluence, with a series of ten-fold dilutions of XMRV in
serum-free medium, followed 36–48 hrs later by fixation of cells in
paraformaldehyde and processing for immunofluorescence using a
rabbit antiserum developed against inactivated XMRV [2].
Typical virus preparations gave titers of approximately 2–5610
6
infectious units/ml. Virus was diluted in serum-free medium and
used to inoculate cells at a multiplicity of infection (MOI) of
approximately 3, in the presence of various antiviral compounds as
described below. LNCaP, a prostate cancer cell line (ATCC,
CRL-1740) and MCF-7 cells were grown to about 50% confluence
in DMEM containing 10% heat inactivated fetal bovine serum,
100 mg/ml penicillin, and 100 IU/ml streptomycin. Cells were
washed twice with Dulbecco’s phosphate buffered saline (DPBS,
Gibco), and incubated with the viral inoculum for 90 min at 37uC
in the presence of 95% air and 5% CO2, cells were washed twice
with DPBS, detached with Trypsin-EDTA (0.25% Trypsin;
Cellgro), and counted. One thousand cells were added to each
well of a 96-well plate, along with an equal volume of medium
containing the retroviral inhibitor at 2-fold the desired concen-
tration. Inhibitors were dissolved in DMSO or water, depending
on their solubility, and were all tested at 0.01 to 100 mM in 10-fold
increments. Where the drug was found to be active at 0.01 mM,
further dilutions from 1 nM to 0.01 nM were tested. Each
inhibitor was tested in duplicate a minimum of three separate
times in MCF-7 cells in a completely blind fashion using coded
compounds, and the results averaged. Active compounds were also
evaluated for antiviral activity in LNCaP cells to confirm activity
in a secondary cell line known to support XMRV replication. For
controls, wells containing water or DMSO at appropriate
concentrations were used.
Assays for cytotoxicity and XMRV replication
Each well was carefully monitored for signs of cellular toxicity
due to the inhibitors by microscopic observation every 24 h. In
addition, cell viability was measured using the CellTiter 96
AQueous One Solution cell proliferation assay according to the
manufacturer (Promega, Madison, Wis). Viral release from the
cells was assayed by measuring RT activity in the supernatant. For
this, supernatant from each well was collected every 24 h and
frozen at 220uC until it was analyzed by RT assay for viral
release as described previously [40]. In brief, oligo(dT)?poly(rA)
primer-template assays were performed in the presence of
radiolabeled [a-
32P]dTTP and Mn
2+. After incubating the viral
supernatants with the RT reaction mix for 1 h at 37uC, samples
were spotted onto DE81 DEAE cellulose paper (Whatman)
and unincorporated label washed away with 26 SSC (16
SSC=0.15 M NaCl and 0.015 M sodium citrate). Virion-
associated RT was analyzed using a Typhoon 9410 Phosphor-
Imager (GE Healthcare) and quantified with the Image J software
(http://rsbweb.nih.gov/ij/). Inhibition of viral release as mea-
sured on day 6 after inoculation was averaged over 3–5
experiments and plotted. The antiviral EC50 and cytotoxic
concentrations (CC50,) was determined from the concentration–
response curve using the median effect method [20]. HIV-1
replication assays were performed as described previously using
peripheral blood mononuclear cells (PBMC) obtained from the
American Red Cross, Atlanta, GA, that were stimulated with
phytohemagglutinin (PHA) for 72 hr [41].
Combination studies
To evaluate whether the antiviral effects of dual drug
combinations of: RAL with TDF or ZDV or L-000870812;
TDF with ZDV or L-000870812; L-000870812 with ZDV were
synergistic, additive or antagonistic, drug combinations at several
constant ratios were evaluated. RAL, L-000870812, ZDV and
TDF were first tested alone to determine the EC50 and EC90
values, at least three times, each in duplicate. For the median-
effect analysis, the compounds were combined at several ratios
based on multiples of their EC50 or EC90 values. For each drug
(alone or in combination), three to four independent experiments
were performed and all samples were processed in duplicate.
Analysis was performed using the software CalcuSyn (Biosoft,
Ferguson, MO, USA) (see Figure 3 for CI values), which allows
automated simulation of synergism and antagonism at all dose
and effect levels and displays the methods of Chou and Talalay [20],
including median effect plot and CI values. Because the high degree
effects are more therapeutically relevant than the low degree of
effects, the additional weighted average CI (CIwt)w a sc a l c u l a t e d ,
which uses the formula: CIwt =[ C I 50 + 2CI75 + 3CI90 +
4CI95]/10, where CI50,C I 75,C I 90,C I 95 are the CI values at 50%,
75%, 90% and 95% inhibition, respectively. [20,42].
Supporting Information
Table S1 EC50, EC90 and CC50 values of compounds active
against XMRV in MCF-7 cells, as tested in XMRV-infected
LNCaP cells. Compounds found to have significant activity in
MCF-7 cells were tested in LNCaP cells for activity. All
compounds were evaluated in duplicate at least three times.
Values shown are average of replicate assays. Corresponding
values in MCF-7 cells are shown for comparison.
Found at: doi:10.1371/journal.pone.0009948.s001 (0.11 MB
TIF)
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